Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Genentech, a member of the Roche Group, announced today that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin in combination with paclitaxel chemotherapy for previously untreated HER2-negative metastatic breast cancer.

30 Jun 2011

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

Dendreon Corporation today announced that the U.S. Food and Drug Administration approved its Los Angeles cancer immunotherapy manufacturing facility, allowing the company to continue to increase the availability of PROVENGE across the U.S. to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.

30 Jun 2011

A.P. Pharma enters into definitive agreements for $24M private placement of common stock and warrants

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that it has entered into definitive agreements with certain new and existing accredited investors providing for a private placement of common stock and warrants in which the Company will receive $24 million in gross proceeds.

29 Jun 2011

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Tibotec Pharmaceuticals today announced that it has entered into a license agreement with Gilead Sciences, Inc., for the development and commercialization of a new once-daily single tablet fixed-dose antiretroviral combination product containing Tibotec's protease inhibitor PREZISTA® (darunavir) and Gilead's cobicistat, an investigational pharmacoenhancing or "boosting" agent.

28 Jun 2011

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

Sanofi announced today data from four studies of its once-daily GLP-1 receptor agonist Lyxumia that is in Phase III clinical development, including data that demonstrates positive results in type 2 diabetes patients not at goal on oral therapies or with basal insulin.

27 Jun 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

In a new post-hoc analysis based on the American Association of Clinical Endocrinologists (AACE/ACE) diabetes algorithm presented at the American Diabetes Association (ADA) 71st Annual Scientific Sessions, significantly more patients with type 2 diabetes treated with JANUMET-tablets achieved blood sugar goals after 18 weeks compared to metformin as initial therapy.

27 Jun 2011

Vaccination against rotavirus decreases hospitalization rates among infants

[Vaccination against rotavirus, a major cause of severe acute gastroenteritis in children, dramatically decreased hospitalization rates for the infection among infants in three U.S. counties, according to a new study published in Clinical Infectious Diseases and now available online.

27 Jun 2011

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.

From Baxter International Inc. 24 Jun 2011

Endo's complete response for new formulation of OPANA ER NDA accepted by the FDA

Endo Pharmaceuticals announced today that it received notification from the U.S. Food and Drug Administration (FDA) that Endo's complete response to the FDA's Jan. 7, 2011 Action Letter relating to Endo's new drug application (NDA) for a new formulation of OPANA ER has been accepted.

24 Jun 2011

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Sanofi-aventis announced today that Health Canada has granted market authorization for Jevtana injection in combination with prednisone for the treatment of patients with metastatic castration resistant prostate cancer, previously treated with a docetaxel-containing treatment regimen.

24 Jun 2011

Reductions in obesity-related medical costs offset cost of gastric banding surgery within 2.25 years

Allergan, Inc. today announced a new study published in the peer-reviewed journal Surgery for Obesity and Related Diseases that found the cost of a gastric banding weight-loss surgery procedure, such as Allergan's LAP-BAND Adjustable Gastric Banding System, was offset by reductions in obesity-related medical costs within 2.25 years for surgery eligible patients with diabetes, and within four years of the procedure for all surgery eligible patients.

23 Jun 2011

MAP to present LEVADEX data on migraine at 15th Congress of IHC

MAP Pharmaceuticals, Inc. today announced that LEVADEX orally inhaled migraine drug will be featured in four poster presentations, including one late-breaker presentation, at the 15th Congress of the International Headache Society (IHC) in Berlin, Germany on June 23-26, 2011.

23 Jun 2011

SNP identification may help predict patients’ susceptibility to postoperative nausea and vomiting

There are several anesthetic complications that may have a hereditary background, including postoperative nausea and vomiting (PONV). Past observations have shown PONV to occur in blood relatives as far back as two to three generations.

23 Jun 2011

Summer safety tips to keep kids safe

Summer fun is in full swing, which coincides with an increase in bumps, bruises, scrapes and possibly worse. To keep kids safe, prevention and first-aid should be at the forefront of parents' minds this summer according to Dr. Karen Judy, Loyola University Health System pediatric safety expert and professor of pediatrics at Loyola University Chicago Stritch School of Medicine.

23 Jun 2011

St. Jude Medical announces results of Genesis neurostimulator trial on chronic migraine

St. Jude Medical, Inc., a global medical device company, today announced study results on the safety and efficacy of peripheral nerve stimulation (PNS) of the occipital nerve for the management of pain and disability associated with chronic migraine, a debilitating condition that affects millions worldwide.

23 Jun 2011

Incivek-combination therapy increases chances of HCV patients achieving viral cure

The drug Incivek, when given in combination with two other medications, can dramatically increase the chances of people chronically infected with untreated genotype 1 hepatitis C virus achieving a viral cure. That's the finding of a study published in the June 23rd issue of the New England Journal of Medicine.

23 Jun 2011

TESARO secures $101M in Series B financing

TESARO, Inc., an oncology-focused biopharmaceutical company, today announced that it has secured $101 million in a Series B financing to advance and expand the Company's cancer product portfolio.

21 Jun 2011

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced today that the European Commission has granted marketing authorization to BYDUREON.

21 Jun 2011

New anti-abuse formulation of painkiller Oxycodone

It has come to health officials’ attention nationwide that there is a serious rise of abuse of painkillers, especially opioids. Federal officials recently stepped up plans to monitor frequent prescribers and users.

21 Jun 2011

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA injection and SYMLIN injection, and its investigational diabetes drug candidates BYDUREON and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28.

21 Jun 2011

Vomiting News and Research

Further Reading

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

A.P. Pharma enters into definitive agreements for $24M private placement of common stock and warrants

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

Vaccination against rotavirus decreases hospitalization rates among infants

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Endo's complete response for new formulation of OPANA ER NDA accepted by the FDA

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Reductions in obesity-related medical costs offset cost of gastric banding surgery within 2.25 years

MAP to present LEVADEX data on migraine at 15th Congress of IHC

SNP identification may help predict patients’ susceptibility to postoperative nausea and vomiting

Summer safety tips to keep kids safe

St. Jude Medical announces results of Genesis neurostimulator trial on chronic migraine

Incivek-combination therapy increases chances of HCV patients achieving viral cure

TESARO secures $101M in Series B financing

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

New anti-abuse formulation of painkiller Oxycodone

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News